Drug intelligence / Profile preview

Fortigen

Development stage: Unknown
Lead developer: FRiLAB
Modality: Small Molecules
Administration: Oral

Overview

**Fortigen** is an oral fixed-dose syrup marketed by FRiLAB as an appetite stimulant and metabolic enhancer. Each 5 mL contains cyproheptadine hydrochloride 2 mg together with riboflavin, pyridoxine, thiamine, nicotinamide, and cyanocobalamin. Cyproheptadine is a first-generation antihistamine and antiserotonergic agent; its histamine- and serotonin-receptor antagonism is used in this product to support appetite stimulation, while the B vitamins provide nutritional supplementation. ([frilab.ch](https://www.frilab.ch/wp-content/uploads/2019/11/Fortigen-En.pdf))

Brand names: Fortigen

Targets

5-HT (Serotonin receptors)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on Fortigen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fortigen.

Explore the full profile